Kancera

2010 Kancera Ab
Karolinska Institutet Science Park, Banvaktsvägen
Solna
171 48

About Kancera

Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera is currently developing drugs for the treatment of leukemia and solid tumors, by regulating the immune system, blocking survival signals in the cancer cell and on addressing cancer metabolism. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 18 people. Kancera shares are traded on NASDAQ First North and the number of shareholders was more than 7500 as of June 30th, 2017. FNCA is Kancera’s Certified Adviser. Professor Carl-Henrik Heldin, Professor Håkan Mellstedt, and MD PhD Charlotte Edenius are board members and Kancera´s scientific advisers.
YEAR FOUNDED:
2010
LEADERSHIP:
CEO: Thomas Olin

8 articles about Kancera

Biopharma Update on the Novel Coronavirus: July 15

7/15/2020

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
Kancera’s Unique Approach to COVID-19: Attack the Fractalkine System

7/14/2020

Thomas Olin, chief executive officer of Kancera, took time to discuss the company, the Fracktalkine pathway and the upcoming clinical trial.
Clinical Catch-Up: May 18-22

5/26/2020

Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
BioSpace Global Roundup, May 21

5/21/2020

Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
BioSpace Global Roundup, Dec. 5

12/5/2019

Companies from across the globe provide updates on their business and pipelines.
BioSpace Global Roundup, Sept. 5

9/5/2019

Companies from across Europe and Asia share updates on their business and pipelines.
Kancera AB Reports Positive Results from a Phase I Study

2/20/2018

Kancera AB is seeing encouraging results from its Phase 1 study with its Lead Immunoregulating Drug Candidate KAND567.
Recipharm AB And Kancera Collaborate To Manufacture Clinical Trial Supply

9/14/2017